Connexin Inhibitor

Gap 26 is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

TAPS is an aminosulfonate-based lysozyme stabilizer and connexin channel inhibitor. TAPS maintains the native structure of lysozyme in aqueous solution at pH 7.0 and significantly protects it from heat-induced denaturation. TAPS directly inhibits the activity of heteromeric connexin 32/connexin 26 channels (Cx32/Cx26) via its protonated form, and this inhibitory effect is dependent on the presence of connexin 26. TAPS reduces connexin channel-mediated solute exchange in a recombinant liposome system, resulting in a decreased degree of liposome density shift in transport-specific separation assays. TAPS is a critical compound for investigating the structure and function of connexin channels.

Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation.

Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

VRT-534 (Compound 3) is a chemical chaperone targeting connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC₅₀s of 19 and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment.

Lufepirsen sodium scrambled negative control is the sequence scrambled negative control of Lufepirsen sodium.

(R,R)-VRT-534 is the (R,R)-enantiomer of VRT-534 (HY-149318). VRT-534 (Compound 3) is a chemical chaperone targeting connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC₅₀s of 19 and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment.

Lufepirsen sodium is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lufepirsen is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.